Compare Enveric Biosciences Inc (ENVB) vs HSBC Holdings plc (HSBC) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Enveric Biosciences Inc vs HSBC Holdings plc — how do they compare? Enveric Biosciences Inc trades at $1.4 (market cap $5.32M), while HSBC Holdings plc trades at $100.67 (market cap $334.99B). The key difference: HSBC Holdings plc is far larger — about 62968× Enveric Biosciences Inc's market cap, and HSBC Holdings plc pays a 3.73% dividend while Enveric Biosciences Inc pays none. Which is the better fit depends on your goals.
| ENVB | HSBC | |
|---|---|---|
Market Cap | $5.32M | $334.99B |
Sector | Health | Technology |
52-Week High | $17.40 | $100.46 |
52-Week Low | $1.28 | $61.30 |
Enterprise Value | $408.82K | — |
Dividend Yield | — | 3.73% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ENVB trades at $1.38, up 4.55% today, with a bearish technical signal from moving averages but neutral oscillators. The company reported a net loss of $8.77M for 2025, though it beat EPS estimates in all four quarters. Recent news highlights participation in investor conferences and progress with its neuroplastogen candidate EB-003, including IND-enabling studies and positive preclinical results.
Outlook hinges on clinical progress, with 75% analyst buy ratings supporting potential upside, but high financial losses and negative ROE/ROA pose significant risks. Investors face volatility from regulatory developments and funding needs, making it speculative despite positive sentiment from recent operational updates.
HSBC trades at $100.72, up 1.48% today, near its 52-week high. Technical indicators show a bullish trend with support at $100 and resistance at $101. The company reported $22.29B net income for 2025 with a 30.81% net margin, though Q1 2026 EPS missed expectations. Recent news highlights strategic moves including a potential Turkey business sale and AI partnerships.
The outlook is cautiously optimistic with strong profitability and analyst buy ratings (38.1%), but risks include execution of global restructuring and regulatory penalties. Earnings growth and strategic focus on core markets are key catalysts for upside.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Enveric Biosciences Inc
Enveric Biosciences is a biotechnology company focused on developing next-generation psychedelic-inspired therapies for mental health and neuropsychiatric disorders.
Read more on ENVB →About HSBC Holdings plc
HSBC is one of the world's largest banking and financial services organizations. It serves customers worldwide through four global businesses: Retail, Commercial, Global Banking, and Private Banking.
Read more on HSBC →
